百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BGNE 百济神州

交易中 11-22 14:38:46 EST

190.01

-4.55

-2.34%

最高192.01	最低189.01	成交量11.22万
今开190.94	昨收194.56	日振幅1.54%
总市值201.87亿	流通市值115.68亿	总股本1.06亿
成交额2,133万	换手率0.18%	流通股本6,089万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":190.005,"timestamp":1732304318339,"preClose":194.56,"halted":0,"volume":112207,"delay":0,"floatShares":60885100,"shares":106246194,"eps":-8.186614,"marketStatus":"交易中","marketStatusCode":2,"change":-4.555,"latestTime":"11-22 14:38:46 EST","open":190.94,"high":192.01,"low":189.01,"amount":21333304.25978,"amplitude":0.015419,"askPrice":190.4,"askSize":202,"bidPrice":189.8,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-8.186614,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732309200000},"adr":1,"adjPreClose":194.56,"adrRate":13,"preHourTrading":{"tag":"盘前","latestPrice":190.01,"preClose":194.56,"latestTime":"09:28 EST","volume":51,"amount":9758.36397,"timestamp":1732285680111},"postHourTrading":{"tag":"盘后","latestPrice":194.56,"preClose":194.56,"latestTime":"19:45 EST","volume":1375,"amount":267471.03,"timestamp":1732236337889},"volumeRatio":0.464998,"impliedVol":0.39,"impliedVolPercentile":0.2341},"requestUrl":"/m/hq/s/BGNE","defaultTab":"news","newsList":[{"id":"2485864544","title":"港股异动 | 百济神州(06160)盘中涨近3% PRMT5抑制剂国内获批临床 明年将来迎密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2485864544","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485864544?lang=zh_cn&edition=full","pubTime":"2024-11-21 10:56","pubTimestamp":1732157809,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州盘中涨近3%，截至发稿，涨2.29%，报120.5港元，成交额1.4亿港元。消息面上，11月19日，据CDE网站显示，百济神州申报的1类新药BGB-58067片获得临床试验默示许可，拟开发治疗晚期实体瘤患者。根据百济神州公开资料，BGB-58067是一款PRMT5抑制剂，为百济神州未来的核心项目之一。根据CDE官网查询，这是该产品首次在中国获批临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","BK0239","BK1161","BK4504","BK4535","BK1583","BK4505","688235","LU1969619763.USD","BGNE","BK1588","06160","BK4139","BK4526","BK4585","BK4548","LU2328871848.SGD","BK1500","BK4588","LU0307460666.USD"],"gpt_icon":0},{"id":"2485102515","title":"百济神州11月20日获南向资金加仓30.42万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485102515","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485102515?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:30","pubTimestamp":1732152616,"startTime":"0","endTime":"0","summary":"11月20日, 南向资金增持百济神州30.42万股。截止当日收盘，港股通共持有百济神州6307.20万股，占流通股4.54%。百济神州近5个交易日下跌1.01%，港股通累计增持329.09万股；近20个交易日下跌11.96%，港股通累计增持697.73万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121093243a249eddc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121093243a249eddc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","BK0239","06160"],"gpt_icon":0},{"id":"2485170656","title":"百济神州：PRMT5抑制剂获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2485170656","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485170656?lang=zh_cn&edition=full","pubTime":"2024-11-21 07:01","pubTimestamp":1732143702,"startTime":"0","endTime":"0","summary":"据不完全统计，当前全球范围内已有10多款PRMT5抑制剂进入到临床试验阶段。根据百济神州公开资料介绍，该公司研发的BGB-58067为第二代MTA协同PRMT5抑制剂，可选择性杀伤MTAP缺失肿瘤细胞，同时避免影响正常血液细胞。据百济神州公开资料介绍，该公司将在2024年推动10个新分子进入临床试验，包括泛KRAS抑制剂、MTA协同PRMT5抑制剂、EGFR降解剂、CDK2抑制剂、ADC和双特异性免疫细胞衔接器等。本次PRMT5抑制剂获批临床，意味着该产品的研发进程迎来重要进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121070236a2499c2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121070236a2499c2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","BK0239","06160"],"gpt_icon":0},{"id":"1145967084","title":"异动解读 | 百济神州与MSN达成专利和解,护航泽布替尼首个自主产品续航,股价盘中大涨5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145967084","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145967084?lang=zh_cn&edition=full","pubTime":"2024-11-20 22:39","pubTimestamp":1732113554,"startTime":"0","endTime":"0","summary":"百济神州今日盘中股价大涨5.65%,引起了市场广泛关注。消息面上,该公司与MSN公司就围绕首个自主研发新药泽布替尼的专利纠纷达成和解,为其核心产品保驾护航,提振了市场对公司长期发展前景的信心。目前,百济神州和MSN达成的和解协议规定,MSN未来不得在2037年6月15日之前销售泽布替尼仿制药。泽布替尼是百济神州创新研发的首个最佳用药BTK抑制剂,已在全球70多个国家和地区获批上市用于治疗多种B细胞恶性肿瘤,曾一度是公司营收主力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 百济神州与MSN达成专利和解,护航泽布替尼首个自主产品续航,股价盘中大涨5.65%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BGNE"],"gpt_icon":0},{"id":"2484411716","title":"百济神州盘中异动 早盘股价大涨5.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484411716","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484411716?lang=zh_cn&edition=full","pubTime":"2024-11-20 22:34","pubTimestamp":1732113252,"startTime":"0","endTime":"0","summary":"北京时间2024年11月20日22时34分，百济神州股票出现异动，股价急速拉升5.70%。截至发稿，该股报198.48美元/股，成交量2.0079万股，换手率0.02%，振幅2.18%。机构评级方面，在所有33家参与评级的机构中，91%的券商给予买入建议，9%的券商给予持有建议，无券商给予卖出建议。百济神州股票所在的生物技术行业中，整体涨幅为0.33%。该信息摘要如下：东吴证券 研报指出， 百济神州 -UQ3销售收入快速增长，经营性现金流转正。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120223412a248c2fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120223412a248c2fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BGNE","688235","BK4526","BK4505","BK4588","BK4504","BK4535","BK4139","BK4548","BK4585"],"gpt_icon":0},{"id":"2484413199","title":"百济神州与MSN达成专利和解 泽布替尼仿制药不得在2037年前销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2484413199","media":"每日经济新闻","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484413199?lang=zh_cn&edition=full","pubTime":"2024-11-20 19:17","pubTimestamp":1732101478,"startTime":"0","endTime":"0","summary":"在诉讼中，MSN没有挑战将于2034年4月到期的BRUKINSA物质成分专利。根据和解协议，百济神州授予MSN不早于2037年6月15日在美国销售BRUKINSA仿制药的权利，但根据此类和解的惯例，可能会加速或延期。根据法律规定，百济神州和MSN将向美国联邦贸易委员会和美国司法部提交和解协议。公司表示，与MSN的和解以及对山德士诉讼的撤回解决了百济神州对通过提交ANDA以寻求批准销售BRUKINSA仿制药的公司提起的所有专利诉讼。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120191842a2485d55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120191842a2485d55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4504","BK4585","BK4588","BK4535","BK4139","BK4526","BK4078","MSN","BK4548","BGNE","BK4505"],"gpt_icon":0},{"id":"2484164960","title":"泽布替尼仿制药不得在2037年之前销售，百济神州与MSN达成专利和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2484164960","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484164960?lang=zh_cn&edition=full","pubTime":"2024-11-20 17:05","pubTimestamp":1732093511,"startTime":"0","endTime":"0","summary":"11月19日， 百济神州 宣布已与MSN Pharmaceuticals和MSN Laboratories Private公司达成了和解协议，解决了与MSN在美国提交的Brukinsa 仿制药 注册申请相关的专利诉讼问题。根据协议条款，MSN将无法在2037年6月15日之前销售Brukinsa的仿制药，但在某些惯例情况下，该日期可能会提前或延后。MSN在诉讼中并未对Brukinsa的药物组合专利提出异议，该专利将于2034年4月到期。此前，百济神州与诺华子公司Sandoz已联合提交了一份协议，以撤销针对Sandoz提交的ANDA而提起的专利诉讼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120170922abd188c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120170922abd188c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BGNE","BK0239","06160"],"gpt_icon":0},{"id":"2484138143","title":"百济神州(06160)上涨5.04%，报118.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484138143","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484138143?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:11","pubTimestamp":1732068696,"startTime":"0","endTime":"0","summary":"11月20日，百济神州(06160)盘中上涨5.04%，截至10:11，报118.8元/股，成交7120.85万元。百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。截至2024年三季报，百济神州营业总收入187.97亿元、净利润-34.54亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/20101145475695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0307460666.USD","BGNE","LU0588546209.SGD","BK1583","BK4588","BK4505","BK4139","BK1588","LU2328871848.SGD","688235","LU1969619763.USD","BK1161","BK0239","BK4548","BK4535","BK4585","BK4504","BK4526","06160","BK1500"],"gpt_icon":0},{"id":"2484134179","title":"百济神州(06160)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2484134179","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484134179?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:01","pubTimestamp":1732010498,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)公布，于2024年11月14 日，董事会薪酬委员会根据2016期权及激励计划的条款向3名承授人授出可认购合共3,628股美国存托股份的购股权并向147名承授人授出涉及合共36,689 股美国存托股份的受限制股份单位。购股权行使价为每股美国存托股份201.28美元(约每股普通股120.46港元)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","BK4526","06160","BK4585","LU0588546209.SGD","BK1500","LU1969619763.USD","BK1583","BK0239","BK4548","BK4588","BK4504","BK1588","688235","BK1161","LU2328871848.SGD","BGNE","BK4139","LU0307460666.USD","BK4535"],"gpt_icon":0},{"id":"2484916150","title":"百济神州盘前涨3% 获多家机构看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2484916150","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484916150?lang=zh_cn&edition=full","pubTime":"2024-11-19 17:52","pubTimestamp":1732009968,"startTime":"0","endTime":"0","summary":"格隆汇11月19日｜百济神州盘前涨3.09%，报193.49美元。交银国际发报告指，百济神州第三季产品销售放量趋势不改，泽布替尼核心适应症新患份额持续扩大。总收入按年增长28.2%至10.02亿美元，经调整non-GAAP经营利润为6563万美元，连续两个季度实现non-GAAP经营利润转正。该行上调百济神州H股目标价至159港元，催化剂即将密集落地。此外，东吴证券研报指出，百济神州Q3销售收入快速增长，经营性现金流转正。","market":"us","thumbnail":"http://n.sinaimg.cn/spider20241119/137/w519h418/20241119/70a8-8232a77be920108c684d6a5f92a7eaa2.png","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/spider20241119/137/w519h418/20241119/70a8-8232a77be920108c684d6a5f92a7eaa2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-11-19/doc-incwqvpn6152277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4505","BK4504","BK4548","BGNE","BK4588","BK4139","BK4526","BK4535","BK4585"],"gpt_icon":0},{"id":"2484930963","title":"百济神州11月18日获南向资金加仓93.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484930963","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484930963?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:30","pubTimestamp":1731979817,"startTime":"0","endTime":"0","summary":"11月18日, 南向资金增持百济神州93.55万股。截止当日收盘，港股通共持有百济神州6234.40万股，占流通股4.49%。百济神州近5个交易日下跌10.46%，港股通累计增持294.31万股；近20个交易日下跌14.95%，港股通累计增持744.48万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093315a2445030&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093315a2445030&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4535","688235","BK4504","BGNE","BK4588","06160","BK4139","BK4505","BK4526","BK4548"],"gpt_icon":0},{"id":"2484564742","title":"一哥的业绩，投资人不买账","url":"https://stock-news.laohu8.com/highlight/detail?id=2484564742","media":"并购菁英汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484564742?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:03","pubTimestamp":1731924185,"startTime":"0","endTime":"0","summary":"按理说，百济神州拳头产品取得强势的增长且公司非GAAP净利润连续第二个季度实现盈利的背景下，公司股价并未像今年二季度业绩公布前后实现市值的显著提升，相反资金却选择了短期内对其进行抛售。显然，百济神州2024Q3费用控制层面让投资者认为有不及预期的地方。尽管百济神州作为海外PD-1市场的后发者，但获批适应症患者数量众多，叠加近日FDA限制已上市部分PD-1在胃癌适应症上的使用，替雷利珠单抗存在一定差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4087","BK4526","688235","BK4504","LU0053666078.USD","BK4535","BK4505","BK4548","BK4107","BK4585","L","06160","CHMP","BGNE"],"gpt_icon":0},{"id":"2484617601","title":"东吴证券：百济神州成长确定性较高，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484617601","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484617601?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:51","pubTimestamp":1731916297,"startTime":"0","endTime":"0","summary":"东吴证券 研报指出， 百济神州 -UQ3销售收入快速增长，经营性现金流转正。Q3 总收入达10.02亿美元，2024Q1-Q3 收入分别为7.5/9.3/10.0亿美元，欧美市场贡献超76%。截至前三季度，GAAP净亏损1.21亿美元，业绩符合的预期。考虑到公司核心产品销售额持续高速增长，维持公司2024/2025/2026 年营业收入为255.3亿元、340.6亿元和423.8亿元的预测。公司催化剂不断兑现，海外市场进一步打开，成长确定性较高，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118160034a2424532&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118160034a2424532&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BGNE","06160"],"gpt_icon":0},{"id":"2484684935","title":"百济神州拟用4.9亿超募资金补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2484684935","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484684935?lang=zh_cn&edition=full","pubTime":"2024-11-17 19:08","pubTimestamp":1731841722,"startTime":"0","endTime":"0","summary":"财中社11月17日电百济神州（688235/06160/BGNE）发布关于使用部分超募资金永久补充流动资金的公告。公司董事会于2024年11月12日审议通过，决定使用超募资金4.9亿元用于永久补充流动资金，此次补流将不超过超募资金总额的30%。公司承诺在补流后的十二个月内不进行高风险投资，也不会为除全资、控股子公司以外的第三方提供财务资助。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411173241787951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK1500","LU2328871848.SGD","BK4504","BK4548","BK4505","BK1588","06160","BK4526","BK4585","BK1161","BK1583","LU0307460666.USD","LU1969619763.USD","BK4535","LU0588546209.SGD","BGNE","BK4588"],"gpt_icon":0},{"id":"2484815436","title":"东吴证券给予百济神州买入评级，2024年三季报点评：海外销售快速放量，血液瘤行业领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2484815436","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484815436?lang=zh_cn&edition=full","pubTime":"2024-11-17 18:37","pubTimestamp":1731839865,"startTime":"0","endTime":"0","summary":"东吴证券11月17日发布研报称，给予百济神州（688235.SH，最新价：165.32元）买入评级。评级理由主要包括：1）事件：销售收入快速增长，经营性现金流转正；2）BTKi领域领导者，BCL2i和BTKCDAC奠定血液瘤龙头地位；3）以替雷利珠单抗为核心，拓展实体瘤新分子。风险提示：销售收入不及预期；海外注册开发失败；和艾伯维的专利纠纷等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411173241784748.html","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411173241784748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","BGNE"],"gpt_icon":0},{"id":"2483369795","title":"交银国际：上调百济神州(06160)目标价至159港元 Q3产品销售及经营持续向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2483369795","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483369795?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:16","pubTimestamp":1731633401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研究报告称，上调百济神州目标价至159港元，基于3Q业绩以及持续强劲的产品放量趋势，上调2024-26年收入预测6-7%，同时上调泽布替尼峰值销售预测4%至54亿。报告中称，公司总收入同比增长28.2%至10.02亿，其中产品收入9.93亿，主要包括：1)泽布替尼全球销售额6.90亿;泽布替尼在美国1/2LCLL新患中的份额不断提升，当前已超过阿卡替尼，位居领先。3Q公司经调整non-GAAP经营利润为6,563万，连续两个季度实现non-GAAP经营利润转正。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BGNE","688235","06160"],"gpt_icon":0},{"id":"2483667583","title":"【券商聚焦】交银国际上调百济神州(06160)目标价 指3Q24产品销售及经营持续向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2483667583","media":"金吾财讯","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483667583?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:01","pubTimestamp":1731632497,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发研报指，百济神州 3Q24总收入同比增长28.2%至10.02亿，其中产品收入9.93亿，主要包括：1）泽布替尼全球销售额6.90亿，其中美国5.04亿，环比增速放缓主因3Q欧美假期出游带来的季节性波动，叠加2Q末1,500万的一次性购药带来高基数影响。3Q公司经调整non-GAAP经营利润为6,563万，连续两个季度实现non-GAAP经营利润转正。该行上调公司美股/港股/A股DCF目标价至265.00美元/159.00港元/179.52元人民币。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/M2ZiNmJjNGMwZDk5N2EzMzdhMmQ3YTNjNTY2NTQwOTU0NTAzNDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/M2ZiNmJjNGMwZDk5N2EzMzdhMmQ3YTNjNTY2NTQwOTU0NTAzNDA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947767","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","BGNE","688235"],"gpt_icon":0},{"id":"2483836337","title":"百济神州拟将英文名称变更为“BeOne Medicines Ltd.”","url":"https://stock-news.laohu8.com/highlight/detail?id=2483836337","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483836337?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:30","pubTimestamp":1731630600,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）发布公告，就存续的目的，董事会拟议将公司英文名称从“BeiGene， Ltd．”变更为“BeOne Medicines Ltd．”并采纳包含拟议公司英文名称变更的拟议瑞士章程。公司的中文名称将保持不变。\n　　公告称，新英文名称彰显公司对研发创新药物，以及通过携手全球各界，服务更多患者从而消除癌症的承诺。董事会相信拟议公司英文名称变更符合公司和股东的整体利益。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-15/doc-incwaxxq9763547.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-15/doc-incwaxxq9763547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06160","BK1588","LU2328871848.SGD","BGNE","BK4588","BK0239","BK4504","BK4505","BK4139","LU1969619763.USD","688235","LU0307460666.USD","BK1161","LU0588546209.SGD","BK1583","BK4535","BK4526","BK4548","BK4585","BK1500"],"gpt_icon":0},{"id":"2483357253","title":"单季度营收超10亿美元，百济神州缘何此时更换英文名？","url":"https://stock-news.laohu8.com/highlight/detail?id=2483357253","media":"21世纪经济报道","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483357253?lang=zh_cn&edition=full","pubTime":"2024-11-15 07:41","pubTimestamp":1731627676,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛上海报道11月14日，百济神州（纳斯达克代码：BGNE；香港联交所代码：06160.HK；上交所代码：688235.SH）宣布，拟将启用新的英文名称BeOneMedicinesLtd.。同时，公司的中文名称“百济神州”保持不变。据悉，新英文名称一旦获得股东批准，百济神州在纳斯达克的股票交易代码将变更为ONC，而在港交所和A股科创板的股票代码将保持不变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411153240288719.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411153240288719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BGNE","06160"],"gpt_icon":0},{"id":"2483355616","title":"高瓴HHLR三季度持仓：加仓中概趋势明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2483355616","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483355616?lang=zh_cn&edition=full","pubTime":"2024-11-15 06:00","pubTimestamp":1731621643,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688235","TCOM","BK1587","LU0737861772.HKD","BEKE","LU0269904917.USD","LU1105468828.SGD","BGNE","LU0106252389.USD","BK4554","LU0348805143.USD","09961","LU2257852520.SGD","LU1226287875.USD","LU0572944931.SGD","TTTN","BK4558","BK4548","LEGN","LU1688375341.USD","BK4501","BABA","LU0011963245.USD","BK1531","NTES","LU0326950275.SGD","LU0823397285.USD","FUTU","06160","LU0251143458.SGD","LU0329678337.USD","LU1008478684.HKD","LU1226287529.USD","LU0327786744.USD","IE0008369823.USD","LU0456846285.SGD","LU2778985437.USD","LU0509642566.USD","LU0594300419.USD","09988","09999","LU1720050803.USD","BK4538","LU2039709279.SGD","NQmain","LU0593848301.USD","BK4577","BK4524","PDD","VIPS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.1182},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.274},{"period":"1year","weight":0.0644},{"period":"ytd","weight":0.0787}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.028699},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.01513},{"month":6,"riseRate":0.555556,"avgChangeRate":0.015441},{"month":7,"riseRate":0.777778,"avgChangeRate":0.136456},{"month":8,"riseRate":0.555556,"avgChangeRate":0.036185},{"month":9,"riseRate":0.555556,"avgChangeRate":0.064683},{"month":10,"riseRate":0.555556,"avgChangeRate":0.004837},{"month":11,"riseRate":0.444444,"avgChangeRate":0.048805},{"month":12,"riseRate":0.375,"avgChangeRate":-0.023463}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,BGNE,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}